

## *syngo* iFlow

Dynamic Flow Evaluation

Answers for life.

**SIEMENS**

“I think *syngo* iFlow imaging is going to be useful in a variety of circumstances. In particular, it is likely to be useful in comparing pre- and post-treatment acquisitions where we are trying to see how flow has changed not just through arteries, but also in the brain parenchyma. *syngo* iFlow\* will also be of help in trying to analyze complex flow patterns as are often seen in obstructive diseases where there are complicated collaterals as well as in arteriovenous fistula and malformations.”

Charles M. Strother, MD

Professor of Radiology

University of Wisconsin School of Medicine and Public Health, Madison, USA

# *syngo* iFlow

## Dynamic flow evaluation


For the first time in the interventional suite, *syngo* iFlow allows the creation of a static image displaying dynamic information, making flow visualization easier.

*syngo* iFlow is a single image that shows the user the history of the contrast media through the vessels, in full color, at the click of a button.



This dynamic flow evaluation provides a greater understanding of the contrast flow within the pathology, greater ease in visualizing the success of a procedure and assists the clinician in image review by showing a complete Digital Subtraction Angiography (DSA) run in a single image.



### Benefits

- A complete DSA series in one color image
- Easily visualize vascular structures
- Demonstrate the early vascularization of tumors
- Clearly demonstrate post-procedural results





In the *syngo* iFlow function, the maximum opacification of each pixel is provided with a time from injection. This time is then represented by a color. It is important to note that the colors (ranging from red to blue) represent early, middle and late flow in the section of the DSA sequence that you are reviewing; the colors do not necessarily relate to the arterial, parenchymal or venous phase of contrast flow. The DSA section you wish to review can easily be selected within the *syngo* iFlow function.





**1** AP projection pre-treatment (a) and post-treatment (b)



**2** Lateral projection pre-treatment (a) and post-treatment (b)

# Stenosis of the left MCA

## History

85-year-old female with history of left hemisphere TIAs and acute left MCA stroke.

## Diagnosis



CTA, CTP and MRA revealed a severe stenosis at the origin of the left MCA with marked decreased perfusion of the left MCA territory. A 2D DSA confirmed the severe MCA stenosis.

## Treatment

Percutaneous transluminal angioplasty and stenting were performed without adverse events. A 2D DSA done at the end of treatment demonstrated approximately 30-40% residual stenosis in the MCA. Flow into the left MCA territory was markedly improved.

## Comments

The improvement in flow to the left MCA distribution with faster flow of contrast through the brain parenchyma is much more easily appreciated on the color-coded images than on the DSA acquisitions. Notice the color of the large vein of Labbe and the middle cerebral vein draining the left middle cerebral territory changing from blue to green on the post-treatment color-coded image (white arrows).



1 AP projection pre-treatment (a) and post-treatment (b)

# Aneurysm coiling and vasospasm

## History

38-year-old male seen 6 days after an acute sub-arachnoid and intra-parenchymal hemorrhage

## Diagnosis

DSA showed a 5-6 mm right middle cerebral aneurysm, a 1.5 mm anterior communicating artery aneurysm. There was also severe vasospasm much worse on the right than on the left.


## Treatment

Both aneurysms were coiled and the vasospasm was also treated.

## Comments

The color-coded image of the right internal carotid DSA prior to treatment shows late opacification of the right cerebral hemisphere parenchyma. The parenchymal opacification is also not uniform. The color-coded image done at the end of treatment shows much earlier and more uniform parenchymal opacification. The impact of the vasospasm treatment on parenchymal blood flow is more easily appreciated on the color-coded images than on the DSA images. Notice the green color in the internal carotid artery on the pre-treatment image and the orange color in the same artery on the post-treatment image. Also note the filling of the dural sinuses on the post-treatment image but not on the pre-treatment images. This indicates improvement in the circulation time with faster flow from the internal carotid artery, through the brain parenchyma and into the dural sinuses. This reflects the decreased resistance resulting from vessel dilatation after treatment of the vasospasm.

1



1 Lateral projection of arterial phase

# Dural arteriovenous fistula

## History

64-year-old female with a history of right-sided headache and diplopia. CT and MRI demonstrated a possible right carotid-cavernous fistula.

## Diagnosis



2D DSA revealed a right-sided dural arteriovenous fistula with arterial supply from both internal and external carotid arteries. The inferior petrosal sinuses appeared to be occluded. Drainage from the cavernous sinuses was retrograde into intracranial veins.

## Treatment



Repeated attempts to gain access into the cavernous sinus through the inferior petrosal sinus were unsuccessful.

## Comments

Color-coded blood flow confirms the right petrosal sinus occlusion (red arrow). The early opacification of the basal vein of Rosenthal (white arrow), the vein of Galen (yellow arrow), Straight Sinus and ipsilateral dural sinuses are also well seen. The extent of the shunting into intracranial veins is much easier to visualize on the color-coded image as compared to DSA.



**1** Lateral projection of arterial phase pre- (a) and post-treatment (b)



**2** Lateral projection of parenchymal phase pre- (a) and post-treatment (b)

# In-stent stenosis

## History

74-year-old woman with a history of recurrent left-hemisphere transient ischemic attacks (TIAs) following previous angioplasty and stenting of a left middle cerebral artery stenosis.

## Diagnosis

A CT perfusion study demonstrated increased transit times and decreased cerebral blood flow of the left cerebral hemisphere. CTA showed evidence of in-stent restenosis. Cerebral angiogram revealed an approximately  $\geq 90\%$  in-stent stenosis of the left M1 extending into the inferior division (M2 segment).



## Treatment

Percutaneous transluminal balloon angioplasty resulted in a reduction of the stenosis by about 50%. There was markedly improved flow into the middle cerebral distribution. The patient did not experience any further TIAs.

## Comments

**Arterial Phase** The lateral projection of the pre-angioplasty angiogram shows slow flow in middle cerebral branches, more in the inferior division than in the superior division (white arrow). After angioplasty flow is much faster in these branches. These changes are easier to visualize on the color-coded image than on the DSA.

**Parenchymal Phase** The lateral projection of the pre-angioplasty angiogram shows slow flow in the inferior division of the middle cerebral artery. There is also incomplete opacification of the middle cerebral territory (white dotted line shows expected limit of MCA territory). The vein of Labbe (red arrows) is not filled and cortical veins from the middle cerebral territory (white arrows) fill more slowly than do veins from the anterior cerebral territory. After angioplasty there is much faster flow in the middle cerebral cortical branches with good opacification of the entire middle cerebral territory. The vein of Labbe and other cortical veins from the middle cerebral territory now fill normally. These changes are much easier seen on the color-coded image than on the DSA.



1 AP (a) and lateral projection (b)

# Arteriovenous malformation (AVM)

## History

40-year-old female with a history of an incidentally found right occipital arteriovenous malformation (AVM).

## Diagnosis



Cerebral angiogram demonstrated a 3 cm right occipital AVM fed from P2 and P3 branches of the right posterior cerebral artery. Venous drainage was into the Galenic system as well as into a cortical vein running parallel with the superior sagittal sinus.

## Treatment

None

## Comments

*syngo* iFlow provides an excellent composite picture of the entire AVM nidus, the feeding arteries and the venous drainage from both the AVM and **normal brain** on one single image. It is easy to visualize the AVM nidus with primary arterial supply from the posterior cerebral artery, the shunting into multiple cortical veins of the right hemisphere (white arrow), the deep venous system (yellow arrow) and cortical veins of the left hemisphere (red arrow). A stenosis in the distal portion of the left transverse sinus is also seen (green arrow). Because of the composite nature of the color-coded image, it is easier to see the relationship between arteries and veins that are filling and emptying at different time points.



1 Lateral projection of left common carotid artery angiogram (a) and AP projection of left occipital angiogram (b)

# Glomus tumor

## History

45-year-old female with a history of pulsatile tinnitus. CT and MRI revealed a left-sided mass at the jugular foramen consistent with a glomus jugulare tumor.

## Diagnosis

DSA done prior to pre-operative embolization showed a typical pattern of vascularity with supply to the tumor from the ipsilateral occipital artery as well as the ascending pharyngeal artery. Venous drainage was into the internal jugular vein with retrograde filling of the petrosal sinus, cavernous sinus and superior ophthalmic vein. Following embolization there was no longer any tumor stain and no abnormal venous drainage.



## Treatment

Embolization was performed by successively selecting each of the feeder branches. An angiogram done at the end of embolization demonstrated no significant residual tumor blush.

## Comments

The pre-embolization color-coded image (1a) shows the venous drainage from the tumor much more clearly than the DSA, with clear visualization of retrograde filling of the inferior petrosal sinus (white arrow) and superior ophthalmic vein (red arrow).

The color-coded image of a selective occipital artery injection (1b) is particularly useful in showing the venous drainage from the tumor. Notice opacification of the jugular vein (white arrow), cavernous sinus (red arrow) and occipital sinuses (yellow arrows) at the same time as opacification of the cutaneous branch of the occipital artery (green arrow); all of these structures have the same color, indicating simultaneous opacification.



1 AP projection (a) and lateral projection (b)

# Dural arteriovenous fistula

## History

60-year-old male with a 5-year history of trigeminal neuralgia.

## Diagnosis



MRI found dural arteriovenous fistula on the right side of cerebellopontine angle. Angiogram further classified it as Type I which is supplied by the Bernasconi-Cassinari artery and drains antegrade into a dilated deep vein and then into the straight sinus and the transverse sinus.

## Treatment



The fistula was treated with transvenous coil embolization via the straight sinus.

## Comments

Thanks to the composite nature of *syngo* iFlow, the entire fistula, the feeding arteries and the venous drainage can be visualized on a single image. It is easy to visualize the fistula with primary arterial supply from the Bernasconi-Cassinari artery (orange arrow), the draining into a dilated deep vein (white arrow) and venous sinuses (red arrows) of the right hemisphere. The composite nature of the color-coded image clearly depicts the relationship between arteries and veins that are filling and emptying at different time points. The distinct color difference between the sagittal sinus and the draining veins and sinuses of the fistula delineates the draining system of the fistula clearly. The graduated color differences illustrate the antegrade flow in the draining veins and sinuses.



1 AP projection pre-treatment (a) and post-treatment (b)



2 Lateral projection pre-treatment (a) and post-treatment (b)

# MCA occlusion

## History

75-year-old male with acute left hemiparesis.

## Diagnosis

CTA revealed right middle cerebral artery (MCA) occlusion (M1 segment) with marked decreased perfusion of the right MCA territory. A 2D DSA confirmed these observations.

## Treatment

After mechanical thrombectomy using the Penumbra System, flow into the right MCA territory was markedly improved. MRI performed one day after treatment revealed infarction of the right striatum.

## Comments


On the composite image it can be easily observed that blood flow was not only restored in the right MCA (red arrows), but also improved in the upstream carotid. This is much more easily appreciated on the color-coded images than on the DSA acquisitions. Flow to part of the MCA territory was not restored after the recanalization (area surrounded by white dotted lines), which was in agreement with the MRI findings after the procedure.

# syngo iFlow – A clinical study

## Study design

The pilot study for *syngo iFlow*\* consisted of six readers, including three expert readers who are experienced neuroradiologists from the University of Wisconsin and three novice readers who are fellows in neuroradiology and residents from the same institute. The readers were asked to evaluate 26 medical cases, consisting of six different pathologies

- Arteriovenous malformation (AVM) and fistula
- Stenosis
- Stroke
- Aneurysm
- Vasospasm
- Tumor



Please note: The pilot study was executed using a pre-release version of *syngo iFlow*

“*syngo* iFlow is a valuable addition to the tools available for the display of 2D DSA acquisitions. At no added X-ray dose or contrast medium, it improves the conspicuity of findings on DSA images. It seems particularly useful in situations where there are complex flow patterns as well as in evaluating acquisitions done prior to and after a therapeutic intervention.”

Charles M. Strother, MD Professor of Radiology  
University of Wisconsin School of Medicine and Public Health, Madison, USA

## Study results

- In more than 20% of the cases, physicians found that *syngo* iFlow made both diagnosis and treatment planning easier than using DSA alone\*
- In more than 20% of the cases, the physicians changed their evaluation of the success of the procedure after using *syngo* iFlow to analyze the opacified blood flow in the post-treatment images\*
- In more than 40% of the cases, physicians found that *syngo* iFlow made the evaluation of post-treatment images easier\*

\*Full statistics will be presented in a future publication.

---

## Acknowledgements

Dr. Charles Strother<sup>1</sup>  
Dr. Arnd Doerfler<sup>2</sup>  
Dr. Marc Dölken<sup>2</sup>  
Frederik Bender<sup>3</sup>  
Yu Deuerling-Zheng<sup>3</sup>  
Kevin Royalty<sup>3</sup>

We wish to acknowledge the contributions of case material to this work by Dr. Beverly Aagaard-Kienitz and Dr. David Niemann at the University of Wisconsin. Special thanks to Kari Pulfer<sup>1</sup>, John Rauch<sup>4</sup>, Gary Martucci<sup>4</sup>, and Christopher Luty<sup>1</sup> for their significant support.

<sup>1</sup> Department of Neuroradiology, University of Wisconsin Hospitals, Madison, USA

<sup>2</sup> Department of Neuroradiology, University of Erlangen-Nuremberg, Erlangen, Germany

<sup>3</sup> Siemens Healthcare, AX Innovations, Germany

<sup>4</sup> Siemens Healthcare, Hoffman Estates, USA

On account of certain regional limitations of sales rights and service availability, we cannot guarantee that all products included in this brochure are available through the Siemens sales organization worldwide. Availability and packaging may vary by country and are subject to change without prior notice. Some/All of the features and products described herein may not be available in the United States.

The information in this document contains general technical descriptions of specifications and options as well as standard and optional features that do not always have to be present in individual cases.

The information presented in these case studies is for illustration only and is not intended to be relied upon by the reader for instruction as to the practice of medicine. All health care practitioners reading this information are reminded that they must use their own learning, training, and expertise in dealing with their individual patients. This material does not substitute for that duty and is not intended by Siemens Medical Systems to be used for any purpose in that regard.

The drugs and doses mentioned herein are consistent with the approval labeling for uses and/or indications of the drug. The treating physician bears the sole responsibility for the diagnosis and treatment of patients, including drugs and doses

prescribed in connection with such use. The operating instructions must always be strictly followed when operating the AX system. The source for the technical data is the corresponding data sheets.

Siemens reserves the right to modify the design, packaging, specifications, and options described herein without prior notice. Please contact your local Siemens sales representative for the most current information.

Note: Any technical data contained in this document may vary within defined tolerances. Original images always lose a certain amount of detail when reproduced.

For accessories, see:  
[www.siemens.com/medical-accessories](http://www.siemens.com/medical-accessories)

#### **Global Business Unit**

Siemens AG  
Medical Solutions  
Angiography, Fluoroscopic  
and Radiographic Systems  
Siemensstr. 1  
91301 Forchheim  
Germany  
Phone: +49 9131 84-0  
[www.siemens.com/healthcare](http://www.siemens.com/healthcare)

#### **Global Siemens Headquarters**

Siemens AG  
Wittelsbacherplatz 2  
80333 Muenchen  
Germany

#### **Global Siemens Healthcare Headquarters**

Siemens AG  
Healthcare Sector  
Henkestr. 127  
91052 Erlangen  
Germany  
Phone: +49 9131 84-0  
[www.siemens.com/healthcare](http://www.siemens.com/healthcare)

#### **Legal Manufacturer**

Siemens AG  
Wittelsbacherplatz 2  
DE-80333 Muenchen  
Germany

[www.siemens.com/healthcare](http://www.siemens.com/healthcare)